Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient

被引:12
作者
Baraniak, Ilona Anna [1 ,2 ]
Reeves, Matthew B. [1 ]
Griffiths, Paul D. [1 ]
机构
[1] UCL Med Sch, Ctr Virol, London, England
[2] UCL Med Sch, Inst Immun & Transplantat, Rowland Hill St, London NW3 2PF, England
基金
英国医学研究理事会;
关键词
cytomegalovirus; gB/MF59; vaccine; interruption of CMV transmission; NK CELLS; TRANSPLANT RECIPIENTS; DISEASE; INFECTION; GANCICLOVIR; PREVENTION; RESISTANCE; VACCINE; QUANTITY; KINETICS;
D O I
10.1002/rmv.1958
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this review article, we consider results suggesting that transmission of human cytomegalovirus (HCMV) from a donor of a solid organ to an immunologically naive individual can be reduced. Two randomized controlled trials have been conducted recently, one of active immunization of recipients pretransplant and another of passive immunization with monoclonal antibodies specific for HCMV given at the time of transplant. Although the available data are encouraging-providing evidence of a reduction in the incidence of HCMV viraemia-they fall short of what would be required to prove definitively that transmission has been completely prevented. Here, we reflect on these studies and propose a set of 5 criteria, which, if satisfied in the future, could be taken as proof that active and/or passive immunization against HCMV effectively interrupts transmission of virus from the donor. We suggest that these criteria are considered when designing future randomized controlled trials.
引用
收藏
页数:8
相关论文
共 43 条
[1]   Cytomegalovirus Vaccines: Current Status and Future Prospects [J].
Anderholm, K. M. ;
Bierle, C. J. ;
Schleiss, M. R. .
DRUGS, 2016, 76 (17) :1625-1645
[2]   Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy [J].
Atabani, S. F. ;
Smith, C. ;
Atkinson, C. ;
Aldridge, R. W. ;
Rodriguez-Peralvarez, M. ;
Rolando, N. ;
Harber, M. ;
Jones, G. ;
O'Riordan, A. ;
Burroughs, A. K. ;
Thorburn, D. ;
O'Beirne, J. ;
Milne, R. S. B. ;
Emery, V. C. ;
Griffiths, P. D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (09) :2457-2464
[3]   NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs [J].
Beziat, Vivien ;
Liu, Lisa L. ;
Malmberg, Jenny-Ann ;
Ivarsson, Martin A. ;
Sohlberg, Ebba ;
Bjorklund, Andreas T. ;
Retiere, Christelle ;
Sverremark-Ekstrom, Eva ;
Traherne, James ;
Ljungman, Per ;
Schaffer, Marie ;
Price, David A. ;
Trowsdale, John ;
Michaelsson, Jakob ;
Ljunggren, Hans-Gustaf ;
Malmberg, Karl-Johan .
BLOOD, 2013, 121 (14) :2678-2688
[4]   Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art [J].
Campos, Ana Bela ;
Ribeiro, Joana ;
Boutolleau, David ;
Sousa, Hugo .
REVIEWS IN MEDICAL VIROLOGY, 2016, 26 (03) :161-182
[5]   Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation [J].
Cope, AV ;
Sabin, C ;
Burroughs, A ;
Rolles, K ;
Griffiths, PD ;
Emery, VC .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1484-1490
[6]  
Cope AV, 1997, J MED VIROL, V52, P200, DOI 10.1002/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.3.CO
[7]  
2-H
[8]   Impact of HCMV infection on NK cell development and function after HSCT [J].
Della Chiesa, Mariella ;
Falco, Michela ;
Muccio, Letizia ;
Bertaina, Alice ;
Locatelli, Franco ;
Moretta, Alessandro .
FRONTIERS IN IMMUNOLOGY, 2013, 4
[9]   Cytomegalovirus latency and reactivation: recent insights into an age old problem [J].
Dupont, Liane ;
Reeves, Matthew B. .
REVIEWS IN MEDICAL VIROLOGY, 2016, 26 (02) :75-89
[10]   Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy [J].
Emery, VC ;
Griffiths, PD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8039-8044